GMED is the ticker symbol for GLOBUS MEDICAL INC, a publicly traded Healthcare sector company listed on NYSE. 13F Pro tracks GMED with AI-powered analysis, an AI quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is GMED a good stock to buy?

13F Pro's AI ranking engine scores GMED at 77.9/100, ranked #58 of 2,925 stocks on a composite quality score built from its SEC filings, covering profitability, growth, balance sheet strength, and free cash flow. The full AI verdict and bull/bear case for GMED is available at https://13fpro.ai/company/GMED. Not investment advice — review the underlying SEC filings before making any trade.

Where does 13F Pro source GMED data?

All GLOBUS MEDICAL INC fundamentals and ownership data come directly from SEC EDGAR. GLOBUS MEDICAL INC files with the SEC under CIK 1237831. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

GLOBUS MEDICAL INC GMED

NYSELarge CapHealthcare

13F Pro quality score

Rank #58 of 2,925TOP 5%

Why it scores 78 Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$789.61M

Quarter to Jun 30

Net income

$151.57M

Quarter to Jun 30

Free cash flow

$176.57M

Quarter to Jun 30

Operating margin

23.1%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026

$9.42B total

BlackRock, Inc.

$853.84M+2.9%

Jupiter Topco LLC

$647.93M--

VANGUARD CAPITAL MANAGEMENT LLC

$403.55M+1.5%

VANGUARD PORTFOLIO MANAGEMENT LLC

$394.61M+2.4%

Invesco Ltd.

$340.52M-0.2%

KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC

$338.14MNew

STATE STREET CORP

$293.54M+3.4%

Sculptor Capital LP

$237.03M-1.9%

JPMORGAN CHASE & CO

$230.76M+5.7%

ALLIANCEBERNSTEIN L.P.

$205.09M+36.0%

BANK OF MONTREAL /CAN/

$191.64M+5.1%

DIMENSIONAL FUND ADVISORS LP

$187.25M+33.9%

GEODE CAPITAL MANAGEMENT, LLC

$170.15M+1.9%

GOLDMAN SACHS GROUP INC

$140.76M+57.4%

ARROWSTREET CAPITAL, LIMITED PARTNERSHIP

$135.63M+88.0%

Boston Trust Walden Corp

$124.31M+25.4%

Boston Partners

$122.85MNew

Allspring Global Investments Holdings, LLC

$119.38M+267.2%

GW&K Investment Management, LLC

$114.82M-2.8%

GENEVA CAPITAL MANAGEMENT LLC

$111.96M-19.5%

WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC

$101.52M-36.1%

CHARLES SCHWAB INVESTMENT MANAGEMENT INC

$98.47M+0.2%

Quantinno Capital Management LP

$96.32M+122.8%

NORGES BANK

$89.05M--

FULLER & THALER ASSET MANAGEMENT, INC.

$88.06M+1.2%

See all 602 institutional holders →

What's Driving GMED's Business? Latest 10-Q Breakdown

38/38 datapoints verified

AI-extracted from the 10-Q filed 2026-08-06 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Q2 net sales rose 5.9% to $789.6M and operating income jumped to $182.4M from $76.1M, but net income fell to $151.6M absent last year's $110.6M bargain purchase gain.

Biggest Revenue Drivers

Musculoskeletal Solutions$763.5M

U.S. Musculoskeletal Solutions sales rose $45.7M, driven by spine implantable devices of $32.3M and neuromonitoring of $10.4M; international added $21.2M

Enabling Technologies$26.1M

Domestic Enabling Technology sales decreased $12.3M, driven by lower unit placement; international rose $3.2M on increased unit placement

Biggest Revenue Drivers

Total revenue: $789.6M+5.9% YoY

Musculoskeletal Solutions$763.5M

U.S. Musculoskeletal Solutions sales rose $45.7M, driven by spine implantable devices of $32.3M and neuromonitoring of $10.4M; international added $21.2M

Enabling Technologies$26.1M

Domestic Enabling Technology sales decreased $12.3M, driven by lower unit placement; international rose $3.2M on increased unit placement

Largest Expense Items

Selling, general and administrative$286.8M-5.5% YoY

Decrease of $19.0M in employee-related expenses, partially offset by a $2.7M increase in provision for litigation

Cost of sales (exclusive of amortization of intangibles)$241.4M-2.9% YoY

Prior-year Nevro inventory step-up amortization of $6.0M and $7.3M lower product costs, offset by $3.5M higher freight

Research and development$36.3M-9.1% YoY

Driven by a $4.0M decrease in employee-related expenses

Amortization of intangibles$29.6M-2.1% YoY

Primarily driven by the finalization of amortization of intangible assets

Margins: Cost of sales fell to 30.6% of net sales from 33.4%, and SG&A to 36.3% from 40.7%, lifting operating income to $182.4M from $76.1M.

Watch Items from the Filing

Enabling Technologies net sales fell to $26.1M from $35.2M; domestic Enabling Technology sales dropped $12.3M on lower unit placement.
U.S. net sales grew only 3.0% to $619.1M while international grew 18.0% to $170.5M; U.S. Nevro sales declined $15.1M.
Pimenta litigation: November 2025 jury verdict of $28.7M in damages; $43.1M liability accrued at December 31, 2025, with appeal filed.
Effective tax rate rose to 20.1% from (7.8%), reflecting prior-period state valuation allowance release and non-taxable bargain purchase gain.
Repurchased 1.6 million shares for $136.1 million at an average $82.96; $253.9 million remains authorized, with no borrowings under the $400.0 million facility.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →

Key Metrics

Revenue

Q2 2026

EDGAR

Net Income

Q2 2026

EDGAR

EPS (Diluted)

Q2 2026

EDGAR

Operating Margin

Q2 2026

EDGAR

ROIC

Q2 2026

EDGAR

Free Cash Flow

Q2 2026

EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/GMED

Earnings Per Share

13fpro.ai/company/GMED

Loading ratio trend…

GLOBUS MEDICAL INC reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Op. marginOperating margin
FY 2025	10-K	$2.9B	$537.9M	16.3%
FY 2024	10-K	$2.5B	$103.0M	6.6%
FY 2023	10-K	$1.6B	$122.9M	8.5%
FY 2022	10-K	$1.0B	$190.2M	22.3%
FY 2021	10-K	$958.1M	$149.2M	17.9%
FY 2020	10-K	$789.0M	$102.3M	14.1%

About GLOBUS MEDICAL INC (GMED): stock profile, AI score and financials

GLOBUS MEDICAL INC (GMED) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GMED at 77.9/100 on a composite quality score built from its SEC filings, placing it at rank #58 of 2,925 stocks — the top 5% of the AI-ranked universe. GMED scores in the top quartile across institutional flow (88.3), balance sheet strength (85.9), profitability (79.3). Shareholder dilution risk is elevated at 42.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), GLOBUS MEDICAL INC reports quarterly revenue of $789.6M, net income of $151.6M, an operating margin of 23.1%. Top institutional holders of GMED by reported 13-F value include BlackRock, Jupiter Topco, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. GMED trades on the NYSE exchange and files with the SEC under CIK 1237831. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GMED daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for GLOBUS MEDICAL INC directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1237831 →

GLOBUS MEDICAL INC GMED

Top Institutional Holders

What's Driving GMED's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Biggest Revenue Drivers

Largest Expense Items

Watch Items from the Filing

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

GMED key financials by period

GMED insiders

Congress trading in GMED

About GLOBUS MEDICAL INC (GMED): stock profile, AI score and financials

GLOBUS MEDICAL INC GMED

Top Institutional Holders

What's Driving GMED's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

GMED key financials by period

Companies similar to GMED

GMED insiders

Congress trading in GMED

About GLOBUS MEDICAL INC (GMED): stock profile, AI score and financials